# Flagship Pioneering

originates biotech platforms from scratch rather than investing in outside pitches — in April 2026 it launched Serif Biomedicines with an initial $50 million commitment to develop "Modified DNA" as a programmable, redosable therapeutic class, following its earlier origination of Moderna and, in 2024, Abiologics.

Source: https://en.bioecon.ru/companies/flagship-pioneering/
Updated: 2026-07-04

- Country: United States

## Technologies

- [Venture studios & biotech incubators](https://en.bioecon.ru/technology/venture-studios-biotech-incubators/)